Current HIV/AIDS Reports

, Volume 8, Issue 3, pp 181–191 | Cite as

Influenza and HIV: Lessons from the 2009 H1N1 Influenza Pandemic

  • Anandi N. Sheth
  • Pragna Patel
  • Philip J. Peters
Article

Abstract

Influenza is a common respiratory disease in adults, including those infected with HIV. In the spring of 2009, a pandemic influenza A (H1N1) virus (pH1N1) emerged. In this article, we review the existing literature regarding pH1N1 virus infection in HIV-infected adults, which suggests that susceptibility to pH1N1 virus infection and severity of influenza illness are likely not increased in HIV-infected adults without advanced immunosuppression or comorbid conditions. The risk of influenza-related complications, however, may be increased in those with advanced immunosuppression or high-risk comorbid conditions. Prevention and treatment of high-risk comorbid conditions and annual influenza vaccination should continue to be part of HIV clinical care to help prevent influenza illness and complications. Additional information about pH1N1 vaccine immunogenicity and efficacy in HIV-infected patients would be useful to guide strategies to prevent influenza virus infection in this population.

Keywords

Influenza Pandemic human immunodeficiency virus Epidemiology Complications of HIV infection and treatment H1N1 

Notes

Acknowledgments

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

We thank Kate Buchacz, PhD, MPH, for review of earlier drafts of this manuscript.

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Beck JM, Rosen MJ, Peavy HH. Pulmonary complications of HIV infection. Report of the fourth NHLBI workshop. Am J Respir Crit Care Med. 2001;164(11):2120–6.PubMedGoogle Scholar
  2. 2.
    Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. New Engl J Med. 2009;360(25):2605–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Bishop JF, Murnane MP, Owen R. Australia’s winter with the 2009 pandemic influenza A (H1N1) virus. New Engl J Med. 2009;361(27):2591–4.PubMedCrossRefGoogle Scholar
  4. 4.
    CDC. Update: influenza activity—United States, 2009–10 season. Morb Mortal Wkly Rep. 2010;59(29):901–8.Google Scholar
  5. 5.
    Klein MB, Lu Y, DelBalso L, Cote S, Boivin G. Influenza virus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis. 2007;45(2):234–40.PubMedCrossRefGoogle Scholar
  6. 6.
    Althoff K, Gange S, Sharp G, et al. Elevated 2009 H1N1 antibody titers in HIV-infected and uninfected women in the US: a sero-study, March 1 to September 30, 2009 [abstract]. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2010:#807LB.Google Scholar
  7. 7.
    • Kok J, Tudo K, Blyth CC, Foo H, Hueston L, Dwyer DE. Pandemic (H1N1) 2009 influenza virus seroconversion rates in HIV-infected individuals. J Acquir Immune Defic Syndr. 2011;56(2):91–4. This Australian study measured the post-pandemic seroprevalence and seroconversion rates of pH1N1 among HIV-infected adults and determined that these rates were similar to those reported from the general community. CD4 cell counts and HIV viral loads were not statistically different between patients who seroconverted and those who did not.PubMedCrossRefGoogle Scholar
  8. 8.
    Gilbert GL, Cretikos MA, Hueston L, Doukas G, O’Toole B, Dwyer DE. Influenza A (H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 southern hemisphere winter. PLoS One. 2010;5(9):e12562.PubMedCrossRefGoogle Scholar
  9. 9.
    Kajaste-Rudnitski A, Galli L, Nozza S, et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS. 2011;25(2):177–83.PubMedCrossRefGoogle Scholar
  10. 10.
    • Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 Monovalent AS03-Adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011;52(2):248–56. This report compared immunogenicity of an adjuvanted pH1N1 vaccine in HIV-infected patients compared with solid-organ transplant recipients and healthy individuals and found that antibody response was similar between HIV-infected persons and healthy individuals.PubMedCrossRefGoogle Scholar
  11. 11.
    UNAIDS. Report on the global AIDS epidemic 2008: HIV and AIDS estimates and data, 2007 and 2001. Available from: http://data.unaids.org/pub/GlobalReport/2008/jc1510_2008_global_report_pp211_234_en.pdf. Accessed 18 Mar 2010.
  12. 12.
    Oliveira W, Carmo E, Penna G, et al. Pandemic H1N1 influenza in Brazil: analysis of the first 34,506 notified cases of influenza-like illness with severe acute respiratory infection (SARI). Euro Surveill. 2009;14(42):19362.Google Scholar
  13. 13.
    Fagard C, Launay O, Boucherie C, et al. H1N1 pandemic flu: incidence and characteristics in HIV-infected adults [abstract]. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011:#905.Google Scholar
  14. 14.
    •• Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Surveill Summ. 2011;60(1):1–24. This report updates recommendations by CDC’s Advisory Committee on Immunization Practices (ACIP) regarding the use of antiviral agents for the prevention and treatment of influenza. This report contains information on treatment and chemoprophylaxis of influenza virus infection and provides a summary of the effectiveness and safety of antiviral treatment medications.Google Scholar
  15. 15.
    Campos-Loza A, Soto-Ramirez L, Sierra-Madero J, et al. New swine origin influenza A in HIV-infected patients during the 2009 outbreak in Mexico City [abstract]. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2010:#801.Google Scholar
  16. 16.
    Martinez E, Marcos M, Hoyo-Ulloa I, et al. Influenza A H1N1 in HIV-infected adults. HIV Med. 2011;12(4):236–45.PubMedCrossRefGoogle Scholar
  17. 17.
    • Ormsby CE, de la Rosa-Zamboni D, Vazquez-Perez J, et al. Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease. AIDS. 2011;25(4):435–9. This study at a tertiary referral center in Mexico City described the clinical outcomes of 30 HIV-infected patients with pH1N1 illness. A significant proportion of these patients had advanced HIV infection, and clinical outcomes were more severe in patients not receiving HAART and patients with concomitant OIs.PubMedCrossRefGoogle Scholar
  18. 18.
    Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. 2004;164(20):2206–16.PubMedCrossRefGoogle Scholar
  19. 19.
    Isais F, Lye D, Llorin R, et al. Pandemic (H1N1) 2009 influenza in HIV-infected adults: clinical features, severity, and outcome. J Infect. 2010;61(5):437–40.PubMedCrossRefGoogle Scholar
  20. 20.
    Perez CM, Dominguez MI, Ceballos ME, et al. Pandemic influenza A (H1N1) in HIV-1-infected patients. AIDS. 2010;24(18):2867–9.PubMedCrossRefGoogle Scholar
  21. 21.
    • Peters P, Skarbinski J, Louie J, et al. HIV-infected hospitalized patients with 2009 pandemic influenza A (H1N1)-United States, spring and summer 2009. Clin Infect Dis. 2011;52(S1):S183–8. This manuscript described the clinical findings of HIV-infected patients hospitalized with pH1N1 in the United States. Hospitalized HIV-infected influenza patients experienced similar rates of ICU admission and death compared with HIV-uninfected patients. This study supports current recommendations to use early empiric influenza antiviral treatment for HIV-infected patients with suspected influenza or pneumonia.PubMedCrossRefGoogle Scholar
  22. 22.
    • Riera M, Payeras A, Marcos MA, et al. Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. AIDS. 2010;24(16):2461–7. This study evaluated the clinical presentation and prognosis of HIV-infected patients hospitalized with pH1N1 infection in Spain. The majority of HIV-infected patients were on HAART and had high CD4 cell counts. In this context the clinical outcomes in HIV-infected patients were similar to non–HIV-infected patients.PubMedCrossRefGoogle Scholar
  23. 23.
    Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160(21):3243–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Shelhamer JH, Gill VJ, Quinn TC, et al. The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med. 1996;124(6):585–99.PubMedGoogle Scholar
  25. 25.
    •• Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003–32. An expert panel of the Infectious Diseases Society of America developed these evidence-based guidelines that encompass diagnostic issues and treatment and chemoprophylaxis for seasonal influenza. They are intended for use by physicians in all medical specialties with direct patient care.PubMedCrossRefGoogle Scholar
  26. 26.
    CDC. Guidance for clinicians on the use of rapid influenza diagnostic tests for the 2010–2011 influenza season. Available at http://www.cdc.gov/flu/pdf/professionals/diagnosis/clinician_guidance_ridt.pdf. Accessed 26 Apr 2011.
  27. 27.
    CDC. Influenza symptoms and laboratory diagnostic procedures. Available at http://www.cdc.gov/flu/professionals/diagnosis/labprocedures.htm. Accessed 26 Apr 2011.
  28. 28.
    CDC. Role of laboratory diagnosis of influenza. Available at http://www.cdc.gov/flu/professionals/diagnosis/labrole.htm. Accessed 26 Apr 2011.
  29. 29.
    Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J. 2003;22(2):164–77.PubMedGoogle Scholar
  30. 30.
    Storch GA. Rapid diagnostic tests for influenza. Curr Opin Pediatr. 2003;15(1):77–84.PubMedCrossRefGoogle Scholar
  31. 31.
    •• Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. New Engl J Med. 2010;362(18):1708–19. This article from the Writing Committee of the WHO Consultation on the Clinical Aspects of Pandemic (H1N1) 2009 Influenza reviewed key issues for clinicians regarding epidemiology, pathogenesis, clinical features, diagnosis, and management of pH1N1 infections.PubMedCrossRefGoogle Scholar
  32. 32.
    Blyth CC, Iredell JR, Dwyer DE. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. New Engl J Med. 2009;361(25):2493.PubMedCrossRefGoogle Scholar
  33. 33.
    • Kok J, Blyth CC, Foo H, et al. Comparison of a rapid antigen test with nucleic acid testing during cocirculation of pandemic influenza A/H1N1 2009 and seasonal influenza A/H3N2. J Clin Microbiol. 2009;48(1):290–1. This study reports reduced sensitivity of rapid antigen tests in detecting pH1N1 virus compared with seasonal influenza subtypes (53% vs 74%), highlighting that negative rapid influenza diagnostic test results should be confirmed with alternative tests if definitive diagnosis is needed.PubMedCrossRefGoogle Scholar
  34. 34.
    Louie JK, Guevara H, Boston E, et al. Rapid influenza antigen test for diagnosis of pandemic (H1N1) 2009. Emerg Infect Dis. 2010;16(5):824–6.PubMedGoogle Scholar
  35. 35.
    • Klein NC, Chak A, Chengot M, Johnson DH, Cunha BA. Fatal case of pneumonia associated with pandemic (H1N1) 2009 in HIV-positive patient. Emerg Infect Dis. 2010;16(1):149–50. This report of a fatal case of pneumonia associated with pandemic (H1N1) 2009 in an HIV-positive patient illustrates the limitations of rapid influenza diagnostic tests (this patient had a false-negative result) and the importance of early empiric influenza antiviral treatment if influenza is suspected.PubMedCrossRefGoogle Scholar
  36. 36.
    Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2009;53(5):619–24.Google Scholar
  37. 37.
    •• Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17. The CDC recommends routine HIV screening of adults, adolescents, and pregnant women in health care settings, and hospital admission for influenza presents an important opportunity for HIV testing in patients aged 13–64 years. In addition, acute HIV infection should be considered in patients with “flu-like” symptoms (especially in patients who report high-risk behavior for HIV infection) and can be diagnosed by detecting HIV RNA in plasma from persons with a negative or indeterminate HIV antibody test.PubMedGoogle Scholar
  38. 38.
    Dosekun O, Kober C, Richardson D, Parkhouse A, Fisher M. It’s not all swine flu…are we missing opportunities to diagnose primary HIV infection in patients with flu symptoms? Int J STD AIDS. 2010;21(2):145–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Barchi E, Prati F, Parmeggiani M, Tanzi ML. Pandemic (H1N1) 2009 and HIV co-infection. Emerg Infect Dis. 2010;16(10):1643–4.PubMedGoogle Scholar
  40. 40.
    Celum CL, Buchbinder SP, Donnell D, et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis. 2001;183(1):23–35.PubMedCrossRefGoogle Scholar
  41. 41.
    Weintrob AC, Giner J, Menezes P, et al. Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. Arch Intern Med. 2003;163(17):2097–100.PubMedCrossRefGoogle Scholar
  42. 42.
    Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis. 2001;32(12):1784–91.PubMedCrossRefGoogle Scholar
  43. 43.
    Neuzil KM, Reed GW, Mitchel Jr EF, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA. 1999;281(10):901–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med. 2001;161(3):441–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302(17):1896–902.PubMedCrossRefGoogle Scholar
  46. 46.
    CDC. Patients hospitalized with 2009 pandemic influenza A (H1N1)—New York City, May 2009. JAMA. 2010;303(7):604–7.Google Scholar
  47. 47.
    Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. New Engl J Med. 2009;361(20):1935–44.PubMedCrossRefGoogle Scholar
  48. 48.
    Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302(17):1872–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Fuhrman C, Bonmarin I, Paty A, et al. Severe hospitalised 2009 pandemic influenza A (H1N1) cases in France, 1 July–15 November 2009. Euro Surveill. 2010;15(2):19463.Google Scholar
  50. 50.
    Nguyen TQ, Gwynn RC, Kellerman SE, et al. Population prevalence of reported and unreported HIV and related behaviors among the household adult population in New York City, 2004. AIDS. 2008;22(2):281–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Lee EH, Wu C, Lee EU, et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York city. Clin Infect Dis. 2010;50(11):1498–504.PubMedCrossRefGoogle Scholar
  52. 52.
    Fowlkes AL, Arguin P, Biggerstaff MS, et al. Epidemiology of 2009 pandemic influenza A (H1N1) deaths in the United States, April–July 2009. Clin Infect Dis. 2011;52 Suppl 1:S60–8.PubMedCrossRefGoogle Scholar
  53. 53.
    • Archer B, Cohen C, Naidoo D, et al. Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases. Euro Surveill. 2009;14(42):19369. This report of 91 pH1N1-related fatalities from South Africa reported that 53% of patients were HIV-infected, but tuberculosis infection and pregnancy were also common. Although CD4 cell counts and comorbid conditions were not reported for HIV-infected patients who died of confirmed pH1N1, this report raises concern that HIV infection could increase influenza mortality in certain settings.Google Scholar
  54. 54.
    Le QM, Wertheim HF, Tran ND, van Doorn HR, Nguyen TH, Horby P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. New Engl J Med. 2010;362(1):86–7.PubMedGoogle Scholar
  55. 55.
    Alonso M, Rodriguez-Sanchez B, Giannella M, et al. Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza. J Clin Virol. 2011;50(2):114–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Graitcer SB, Gubareva L, Kamimoto L, et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg Infect Dis. 2011;17(2):255–7.PubMedGoogle Scholar
  57. 57.
    Infectious Diseases Society of America. Influenza H1N1: frontline questions and expert opinion answers. Arlington: Infectious Diseases Society of America; 2009. Available from: http://www.idsociety.org/Content.aspx?id=15743. Accessed 16 Mar 2011.Google Scholar
  58. 58.
    Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. New Engl J Med. 1997;337(13):874–80.PubMedCrossRefGoogle Scholar
  59. 59.
    Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis. 1999;180(2):254–61.PubMedCrossRefGoogle Scholar
  60. 60.
    Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355(9218):1845–50.PubMedCrossRefGoogle Scholar
  61. 61.
    Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283(8):1016–24.PubMedCrossRefGoogle Scholar
  62. 62.
    McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45(12):1568–75.PubMedCrossRefGoogle Scholar
  63. 63.
    Dominguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302(17):1880–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Lee N, Chan PKS, Hui DSC, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200(4):492–500.PubMedCrossRefGoogle Scholar
  65. 65.
    Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282(13):1240–6.PubMedCrossRefGoogle Scholar
  66. 66.
    CDC. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis—North Carolina, 2009. Morb Mortal Wkly Rep. 2009;58(35):969–72.Google Scholar
  67. 67.
    Hill-Cawthorne GA, Schelenz S, Lawes M, Dervisevic S. Oseltamivir-resistant pandemic (H1N1) 2009 in patient with impaired immune system. Emerg Infect Dis. 2010;16(7):1185–6.PubMedCrossRefGoogle Scholar
  68. 68.
    King Jr JC, Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis. 2000;181(2):725–8.PubMedCrossRefGoogle Scholar
  69. 69.
    • Feiterna-Sperling C, Edelmann A, Nickel R, et al. Pandemic influenza A (H1N1) outbreak among 15 school-aged HIV-1-infected children. Clin Infect Dis. 2010;51(11):e90–4. This pH1N1 outbreak investigation among 15 HIV-infected children in Germany documents duration of viral shedding similar to what has been reported in the general population and demonstrates reduced duration of shedding with oseltamivir treatment in this population.PubMedCrossRefGoogle Scholar
  70. 70.
    Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 1999;44(Suppl B):23–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. New Engl J Med. 2000;343(18):1282–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285(6):748–54.PubMedCrossRefGoogle Scholar
  73. 73.
    Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1–62.PubMedGoogle Scholar
  74. 74.
    •• Anema A, Mills E, Montaner J, Brownstein JS, Cooper C. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med. 2008;9(1):57–61. This meta-analysis assessed clinical efficacy of seasonal influenza vaccine in HIV-infected persons and found the pooled relative risk reduction in prevention of influenza by vaccination from three studies (including one randomized controlled trial) was 65% (95% CI 36%–82%).PubMedCrossRefGoogle Scholar
  75. 75.
    • Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011;52(1):128–37. This randomized, double-blind, placebo-controlled trial of trivalent, inactivated influenza vaccine among HIV-infected adults was the first influenza vaccine trial reported from Africa and demonstrated an efficacy of 75.5% without affecting CD4 cell count or HIV viral load.PubMedCrossRefGoogle Scholar
  76. 76.
    • Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis. 2011;52(1):138–46. This prospective study compared immunogenicity of monovalent pH1N1 vaccine in HIV-infected versus HIV-uninfected persons and found that, despite having high CD4 cell counts, HIV-infected persons were less likely to achieve protective antibody titer.PubMedCrossRefGoogle Scholar
  77. 77.
    Amendola A, Boschini A, Colzani D, et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol. 2001;65(4):644–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Brydak LB, Calbecka M. Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Leuk Lymphoma. 1999;32(3–4):369–74.PubMedGoogle Scholar
  79. 79.
    Kroon FP, Rimmelzwaan GF, Roos MT, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS. 1998;12(17):F217–23.PubMedCrossRefGoogle Scholar
  80. 80.
    Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med. 1995;182(6):1727–37.PubMedCrossRefGoogle Scholar
  81. 81.
    Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine. 2002;20 Suppl 5:B29–32.PubMedCrossRefGoogle Scholar
  82. 82.
    Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis. 2009;48(10):1402–12.PubMedCrossRefGoogle Scholar
  83. 83.
    Tebas P, Frank I, Lewis M, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS. 2010;24(14):2187–92.PubMedCrossRefGoogle Scholar
  84. 84.
    Yamanaka H, Teruya K, Tanaka M, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39(2):167–73.PubMedGoogle Scholar
  85. 85.
    Atashili J, Kalilani L, Adimora AA. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis. 2006;6:138.PubMedCrossRefGoogle Scholar
  86. 86.
    Bickel M, Wieters I, Khaykin P, et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS. 2010;24(9):F31–5.PubMedCrossRefGoogle Scholar
  87. 87.
    Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis. 2011;52(1):122–7.PubMedCrossRefGoogle Scholar
  88. 88.
    Durier C, Desaint C, Colin de Verdiere N, et al. Durability of immune response after vaccination with 2 doses of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant in HIV+ adults: ANRS 151 randomized HIFLUVAC trial [abstract]. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011:#909.Google Scholar
  89. 89.
    Orlando G, Pariani E, Mazza F, et al. Pandemic influenza vaccine in adult HIV-1-infected patients. AIDS. 2010;24(13):2142–3.PubMedCrossRefGoogle Scholar
  90. 90.
    Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One. 2011;6(1):e16496.PubMedCrossRefGoogle Scholar
  91. 91.
    Cooper C, Klein M, Walmsley S, Hasse D, Scheifele D, Network PHAoC-CIoHRIR. A randomized trial to compare the immunogenicity and efficacy of adjuvanted pandemic H1N12009 vaccine with or without booster in HIV+ adults [abstract]. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011:#907.Google Scholar
  92. 92.
    Santini-Oliveira M, Camacho L, Souza T, et al. Immunogenicity to an H1N1 adjuvanted influenza vaccine in HIV-infected adults: 2 single vs. 2 double doses: the VIP-H1N1 study [abstract]. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011:#910.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Anandi N. Sheth
    • 1
    • 3
  • Pragna Patel
    • 2
  • Philip J. Peters
    • 2
  1. 1.Division of Infectious Diseases, Department of MedicineEmory University School of MedicineAtlantaUSA
  2. 2.Division of HIV/AIDS PreventionCenters for Disease Control and PreventionAtlantaUSA
  3. 3.AtlantaUSA

Personalised recommendations